| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6258795 | BTG INTL | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(9 months ago) | |
Xuriden is owned by Btg Intl.
Xuriden contains Uridine Triacetate.
Xuriden has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Xuriden are:
- US6258795
Xuriden was authorised for market use on 04 September, 2015.
Xuriden is available in granule;oral dosage forms.
Drug patent challenges can be filed against Xuriden from 05 September, 2019.
The generics of Xuriden are possible to be released after 10 July, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Sep 04, 2022 |
| Orphan Drug Exclusivity(ODE-98) | Sep 04, 2022 |
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2020 |
Drugs and Companies using URIDINE TRIACETATE ingredient
NCE-1 date: 05 September, 2019
Market Authorisation Date: 04 September, 2015
Treatment: NA
Dosage: GRANULE;ORAL
More Information on Dosage
XURIDEN family patents
